Introduction to the Conference
Welcome/Overview
The first four International Conferences on Bipolar Disorder
each have represented a unique opportunity for researchers from around the world
to share new information on the pathophysiology, assessment and treatment of
bipolar illness, as well as on psychobiological and psychosocial vulnerability
factors, and recent findings in epidemiology and clinical course. Renewed
interest in manic-depressive illness on the part of governmental funding
agencies, foundations, and the pharmaceutical industry, has stimulated a quantum
increase in the speed with which new information on bipolar disorder is becoming
available. Thus, the Fifth International Conference on Bipolar Disorder is
planned for June 12 to 14, 2003.
The conference will present information on the following
topics:
• Bipolar depression
• Comorbidity
• Neuroscience
• Genetics
• Aross-the-life-span issues of bipolar disorder
• Update on large multisite trials
Because of their great popularity, the conference will expand
the number of “Ask the Experts” question-and-answer sessions. As in the past,
poster sessions will be held on the evenings of June 12 and 13. The
well-received “Rapid Communications” sessions, included in the Fourth
International Conference, will be repeated this year.
Presentations during the first two days of the conference will
be technical and geared toward academic researchers and research-oriented
clinicians. Psychiatrists, psychologists, neuroscientists, and pharmacologists
interested in bipolar disorder should find the content of this first phase of
the conference useful in their research and practice.
The third day of the conference, which will include an
international advocacy forum and advanced psychotherapy workshops focusing on
cognitive behavioral therapy, family issues for adolescents, and interpersonal
psychotherapy, as well as “Ask the Experts” sessions, will be appropriate to
audiences that include psychiatrists, psychologists, social workers, nurses, and
other mental health care workers, as well as individuals who have bipolar
disorder and their families. Several workshops will be focused on issues
relevant to advocacy groups for bipolar disorder.
We look forward to your participation in the conference.
David J. Kupfer, M.D.
Educational Objectives
At the conclusion of this program, participants should be able
to:
• Describe new approaches to the pharmacotherapy and
psychotherapy of
bipolar disorder.
• Distinguish between the issues related to short and long-term treatment of
bipolar depression.
• Explain key issues from the updates on genetics and neurobiology.
• Discuss the life-span implications of bipolar disorder.
Course Directors
Ellen Frank, Ph.D.
University of Pittsburgh School of
Medicine
Pittsburgh, Pennsylvania
Samuel A.
Gershon, M.D.
University of Pittsburgh School of Medicine
Pittsburgh, Pennsylvania
David J.
Kupfer, M.D.
University of Pittsburgh School of Medicine
Pittsburgh, Pennsylvania
Michael E.
Thase, M.D.
University of Pittsburgh School of Medicine
Pittsburgh, Pennsylvania
International Planning Committee
Valentim Gentil, M.D., Ph.D.
University of São Paulo Medical School
São Paulo, Brazil
Giovanni de Girolamo, M.D.
National Institute of Health
National Mental Health Project
Rome, Italy
Guy Goodwin, M.D.
University Department of Psychiatry
Warneford
Hospital
Oxford,
United Kingdom
Fouzia Laghrissi-Thode, M.D.
F. Hoffman-LaRoche Ltd.
Basel,
Switzerland
Bruno Müller-Oerlinghausen, Dr.med.
Freie Universitaet Berlin
Berlin,
Germany
Per Vestergaard, Dr.Med.Sc.
Aarhus
University, Psychiatric Hospital
Risskov,
Denmark
Eduard Vieta, M.D., Ph.D.
University of Barcelona
Barcelona, Spain
Faculty
Hagop S. Akiskal, M.D.
University of California at San Diego
La Jolla, California
Jules Angst, M.D.
Zurich University Psychiatric Hospital
Zurich, Switzerland
David A. Axelson, M.D.
University of Pittsburgh School of Medicine
Pittsburgh, Pennsylvania
Mark S. Bauer, M.D.
Brown University School of Medicine Providence VA Medical Center Providence,
Rhode Island
Michael Berk, M.D., Ph.D.
University of Melbourne
Melbourne, Australia
Wade Berrettini, M.D., Ph.D.
University of Pennsylvania School of Medicine
Philadelphia, Pennsylvania
Boris Birmaher, M.D.
University of Pittsburgh School of Medicine
Pittsburgh, Pennsylvania
Charles L. Bowden, M.D.
University of Texas Health Sciences Center at San Antonio
San Antonio, Texas
Charlotte Brown, Ph.D.
University of Pittsburgh School of Medicine
Pittsburgh, Pennsylvania
Joseph Calabrese, M.D.
Case Western Reserve University School of Medicine
Cleveland, Ohio
Donna J. Carothers
International Society for Bipolar Disorders
Pittsburgh, Pennsylvania
Giovanni B. Cassano, M.D.
University of Pisa
Pisa, Italy
Paula J. Clayton, M.D.
University of New Mexico School of Medicine
Albuquerque, New Mexico
University of Minnesota Medical School
Minneapolis, Minnesota
John R. Geddes, M.D. FRCPsych
University of Oxford
Warneford Hospital
Oxford, United Kingdom
Valentim Gentil, M.D., Ph.D.
University of São Paulo Medical School
São Paulo, Brazil
Giovanni de Girolamo, M.D.
National Institute of Health
National Mental Health Project
Rome, Italy
Joseph F. Goldberg, M.D.
Weill Medical College of Cornell University
New York, New York
Guy Goodwin, M.D.
University Department of Psychiatry
Warneford Hospital
Oxford, United Kingdom
Martha Hellander
Child and Adolescent Bipolar Foundation
Wilmette, Illinois
Thomas R. Insel, M.D.
National Institute of Mental Health
Bethesda, Maryland
Paul E. Keck Jr., M.D.
University of Cincinnati College of Medicine
Cincinnati, Ohio
Athanasios Koukopoulos, M.D.
Centro Lucio Bini
Rome, Italy
Fouzia Laghrissi-Thode, M.D.
F. Hoffman-La Roche Ltd.
Basel, Switzerland
Brenda E. Lee
Mental Health Association of Allegheny County
Pittsburgh, Pennsylvania
Lydia Lewis
Depression and Bipolar Support Alliance
Chicago, Illinois
Husseini K. Manji, M.D.
National Institute of Mental Health
Bethesda, Maryland
Lauren B. Marangell, M.D.
Baylor College of Medicine
Houston, Texas
David J. Miklowitz, Ph.D.
University of Colorado at Boulder
Boulder, Colorado
Philip Mitchell, M.D., FRANZCP, FRCPsych
University of New South Wales
Sydney, Australia
Paolo Lucio Morselli, M.D.
Fondazione IDEA and GAMIAN-Europe
Milan, Italy
Bruno Müller-Oerlinghausen, Dr.med.
Freie Universitaet Berlin
Berlin, Germany
Michael Otto, Ph.D.
Harvard Medical School
Boston, Massachusetts
Pamela B. Peele, Ph.D.
University of Pittsburgh
Pittsburgh, Pennsylvania
Noreen Reilly-Harrington, Ph.D.
Harvard Medical School
Boston, Massachusetts
Alessandro Rotondo, M.D.
University of Pisa
Pisa, Italy
Gary S. Sachs, M.D.
Harvard Medical School
Boston, Massachusetts
Jan Scott, M.D., FRCPsych
Institute of Psychiatry
London, United Kingdom
Kenneth I. Shulman, M.D.
University of Toronto Faculty of Medicine
Toronto, Canada
Gregory E. Simon, M.D., M.P.H.
Center for Health Studies Group Health Cooperative
Seattle, Washington
Holly Swartz, M.D.
University of Pittsburgh School of Medicine
Pittsburgh, Pennsylvania
Mauricio Tohen, M.D., Dr.P.H.
Lilly Research Laboratories
Indianapolis, Indiana
Harvard Medical School
Boston, Massachusetts
Leonardo Tondo, M.D.
Harvard Medical School
Boston, Massachusetts
University of Cagliari
Cagliari, Italy
Per Vestergaard, Dr.Med.Sc.
Aarhus University, Psychiatric Hospital
Risskov, Denmark
Eduard Vieta, M.D., Ph.D.
University of Barcelona
Barcelona, Spain
Adele Viguera, M.D.
Harvard Medical School
Boston, Massachusetts
Robert M. Wettstein, M.D.
University of Pittsburgh School of Medicine
Pittsburgh, Pennsylvania
Lakshmi N. Yatham, M.B., FRCPC
University of British Columbia
Vancouver, British Columbia, Canada
Allan H. Young, M.D., Ph.D.
University of New Castle
New Castle upon Tyne, United Kingdom
Rapid Communications Session Speakers
Caleb M. Adler, M.D.
University of Cincinnati College of Medicine
Cincinnati, Ohio
Martin Alda, M.D., FRCP(C)
Dalhousie University
Halifax, Nova Scotia, Canada
Vivienne Curtis, M.D.
Institute of Psychiatry
De Crespigny Park
London, United Kingdom
Russell D'Souza, M.D.
Mental Health Research Institute
Melbourne, Australia
Howard H. Fenn, M.D.
VA Health Care System
Menlo Park, California
Robert L. Findling, M.D.
Case Western Reserve University School of Medicine
Cleveland, Ohio
John R. Geddes, M.D., FRCPsych
University of Oxford
Warneford Hospital
Oxford, United Kingdom
S. Nassir Ghaemi, M.D.
Harvard Medical School
Boston, Massachusetts
Chantal Henry, M.D., Ph.D.
Hopital Charles Perrens
Bordeaux, France
Steven H. Jones, Ph.D.
University of Manchester
Manchester, England
Susan L. McElroy, M.D.
University of Cincinnati College of Medicine
Cincinnatii, Ohio
Martin Preisig, M.D.
Psychiatric University Department
Site de Cery
Prilly-Lausanne, Switzerland
Lars O. Scharer, M.D.
University of Freiburg
Freiburg, Germany
Gregory E. Simon, M.D., M.P.H.
Center for Health Studies
Group Health Cooperative
Seattle, Washington
Ari E. Zaretsky, M.D., F.R.C.P.C.
University of Toronto
Toronto, Canada
Disclosure Statement
Presenters for this program, have been requested
to identify significant financial or other relationships with manufacturer(s) of
any commercial product(s) or with providers(s) of any commercial service(s)
which, in the context of their topics, could be perceived as real or apparent
conflicts of interest.
The following information was disclosed:
Caleb M. Adler, M.D.
Consultant: Bristol-Myers Squibb Company
Hagop S. Akiskal, M.D.
Grant/Research Support: Eli Lilly and
Company
Consultant: Abbott Laboratories, Janssen Pharmaceutica, Eli Lilly and
Company
Speakers' Bureau: Abbott Laboratories, GlaxoSmithKline, Janssen
Pharmaceutica, Eli Lilly and Company
Michael Berk, M.D., Ph.D.
Grant/Research Support: Stanley
Foundation
Charles L. Bowden, M.D.
Grant/Research Support: Abbott
Laboratories, Bristol-Myers Squibb Company, Glaxo Wellcome, Janssen
Pharmaceutica, Lilly Research, National Institute of Mental Health,
Parke-Davis, R.W. Johnson Pharmaceutical Institute, Smith Kline Beecham,
Stanley Foundation
Consultant: Abbott Laboratories, Glaxo Wellcome, Janssen Pharmaceutica,
Lilly Research, Sanofi Synthelabo, UCB Pharma, Inc.
Speakers' Bureau: Abbott Laboratories, Astra Zeneca Pharmacueticals,
Glaxo Wellcome, Janssen Pharmaceutica, Lilly Research, Pfizer, Inc.
Joseph R. Calabrese, M.D.
Grant/Research Support: Abbott
Laboratories, CIBA-GEIBY, GlaxoSmithKline, Janssen Pharmaceutica, Lilly
Research Laboratories, MacArthur Foundation, Merck, National Alliance for
Research in Schizophrenia and Affective Disorders, National Institute of
Mental Health, Parke-Davis Pharmaceuticals, Robert Wood Johnson,
Pharmaceutical Research Institute, Sandoz Pharmaceuticals Corporation,
SmithKline Beecham Pharmaceuticals, Stanley Foundation, Tap Holdings, Inc.,
UCB Pharma, Wyeth Ayerst Pharmaceuticals
Consultant: Abbott Laboratories, AstraZeneca Pharmaceuticals,
Bristol-Myers Squibb/Otsuka, GlaxoSmithKline, Janssen Cilag, Eli Lilly and
Company, Novartis, Parke-Davis/Warner Lambert, Robert Wood Johnson
Pharmaceutical Research Institute Shire Labs, SmithKline, TAP Holdings, Teva
Pharmaceuticals, UCB
Paula J. Clayton, M.D.
Grant/Research Support: Forest
Laboratories
Consultant: Forest Laboratories
Speakers' Bureau: Forest Laboratories
Stockholder: Minor
Robert L. Findling, M.D.
Grant/Research Support: Abbott
Laboratories, GlaxoSmithKline, Solvay Pharmaceuticals
Consultant: GlaxoSmithKline
S. Nassir Ghaemi, M.D.
Grant/Research Support: Abbott
Laboratories, AstraZeneca Pharmaceuticals, Janssen Pharmaceutica, Novartis
Consultant: AstraZeneca Pharmaceuticals, GlaxoSmithKline, Janssen
Pharmaceutica
Speakers' Bureau: Abbott Laboratories, AstraZeneca Pharmaceuticals,
Forest Laboratories, GlaxoSmithKline, Janssen Pharmaceutica, Eli Lilly and
Company
Joseph F. Goldberg, M.D.
Grant/Research Support: Abbott
Laboratories, AstraZeneca Pharmaceuticals, Bristol-Myers Squibb, Forest
Laboratories, GlaxoSmithKline, Janssen Pharmaceutica, Eli Lilly and Company,
Novartis, Ortho-McNeil, Pfizer, UCB Pharma
Consultant: Abbott Laboratories, AstraZeneca Pharmaceuticals,
Bristol-Myers Squibb, GlaxoSmithKline, Janssen Pharmaceutica, Eli Lilly and
Company, Novartis, Ortho-McNeil, Pfizer, UCB Pharma
Speakers'Bureau: Abbott Laboratories, AstraZeneca Pharmaceuticals,
Bristol-Myers Squibb, GlaxoSmithKline, Janssen Pharmaceutica, Eli Lilly and
Company, Novartis
Guy Goodwin, M.D.
Grant/Research Support: Sanofi
Synthelabo
Consultant: GlaxoSmithKline
Paul E. Keck, Jr., M.D.
Grant/Research Support: Abbott
Laboratories, AstraZeneca Pharmaceuticals, Bristol-Myers Squibb Company,
GlaxoSmithKline, Elan, Eli Lilly and Company, Merck, National Institute of
Mental Health (NIMH), National Institute of Drug Abuse (NIDA), Organon,
Pfizer, Inc., Stanley Medical Research Institute (SMRI), UCB Pharma
Consultant: Abbott Laboratories, AstraZeneca Pharmaceuticals,
Bristol-Myers Squibb Company, GlaxoSmithKline, Janssen Pharmaceutica, Eli
Lilly and Company, Novartis, Ortho-McNeil, Pharmacia, Pfizer, Inc., UCB Pharma,
Shire, Solvay Pharmaceuticals, Wyeth-Ayerst
David J. Kupfer, M.D.
Other Financial or Material Support:
Advisory Boards: Forest Laboratories, Eli Lilly and Company, Pfizer, Inc.
Fouzia Laghrissi-Thode, M.D.
Stockholder: Novartis Ltd., F. Hoffman-LaRoche
Lauren B. Marengell, M.D.
Grant/Research Support: Cyberonics, Eli
Lilly and Company, Martek Biosciences
Consultant: Bristol-Myers Squibb Company, Cyberonics, Forest
Pharmaceuticals, Glaxo Wellcome SmithKline, Janssen Pharmaceutica, Eli Lilly
and Company, Novartis Pharmaceuticals Corporation, Wyeth Ayerst Laboratories
Other Financial or Material Support: Honoraria from: AstraZeneca
Pharmaceuticals, Bristol-Myers Squibb Company, Cyberonics, Forest
Pharmaceuticals, Glaxo Wellcome SmithKline, Janssen Pharmaceutica, Eli Lilly
and Company, Novartis Pharmaceuticals Corporation, Pharmacia & Upjohn Company,
Wyeth-Ayerst Laboratories
Susan L. McElroy, M.D.
Grant/Research Support: Ortho McNeil
Consultant: Ortho McNeil
Speakers' Bureau: Ortho McNeil
Michael Otto, Ph.D.
Grant/Research: GlaxoSmithKline, Eli
Lilly and Company, Pfizer, Inc.
Consultant: Janssen Pharmaceutica, Pfizer, Inc., Wyeth-Ayerst
Gary S. Sachs, M.D.
Grant/Research Support: Abbott
Laboratories, Janssen Pharmaceutica
Consultant: Abbott Laboratories, AstraZeneca Pharmaceuticals,
Bristol-Myers Squibb Company, Elan, Glaxo Pharmaceuticals, Janssen
Pharmaceutica, Eli Lilly and Company, Novartis, Sanofi, Sigma Tau
Other Financial or Material Support: Honoraria from: Abbott
Laboratories, AstraZeneca Pharmaceuticals, Bristol-Myers Squibb Company, Glaxo
Pharmaceuticals, Janssen Pharmaceutica, Eli Lilly and Company, Novartis,
Pfizer, Inc., Sanofi, Solvay Pharmaceuticals
Lars O. Scharer, M.D.
Other Financial or Material Support:
Computer nach Mass, Systemhaus, GmbH
Gregory Simon, M.D.
Grant/Research Support: Eli Lilly and
Company, Solvay Pharmaceuticals
Mauricio Tohen, M.D.
Other Financial or Material Support:
Fulltime Employee: Eli Lilly and Company
Leonardo Tondo, M.D.
Grant/Research Support: Stanley Medical
Research Institute, NARSAD
Consultant: IFI, Italia
Eduard Vieta, M.D., Ph.D.
Grant/Research Support: GlaxoSmithKline,
Janssen Pharmaceutica, Eli Lilly and Company, Novartis, Pfizer, Inc., UCB
Consultant: AstraZeneca Pharmaceuticals, Janssen Pharmaceutica, Eli
Lilly and Company, Lundbeck, Sanofi
Speakers' Bureau: AstraZeneca Pharmaceuticals, Bristol-Myers Squibb
Company, Janssen Pharmaceutica, Eli Lilly and Company
Lakshmi N. Yatham, M.B., FRCPC
Grant/Research Support: AstraZeneca
Pharmaceuticals, Bristol-Myers Squibb Company, GlaxoSmithKline, Janssen Cilag,
Eli Lilly and Company
Consultant: AstraZeneca Pharmaceuticals, Bristol-Myers Squibb Company,
GlaxoSmithKline, Janssen Cilag, Eli Lilly and Company
Speakers' Bureau: AstraZeneca Pharmaceuticals, Bristol-Myers Squibb
Company, GlaxoSmithKline, Janssen Cilag, Eli Lilly and Company
No significant financial relationships with
commercial entities were disclosed by:
Martin Alda, M.D., FRCP(C)
Jules Angst, M.D.
David A. Axelson, M.D.
Mark S. Bauer, M.D.
Wade Berretini, M.D.
Boris Birmaher, M.D.
Charlotte Brown, Ph.D.
Donna J. Carothers
Giovanni B. Cassano, M.D.
Vivienne Curtis, M.D.
Russell D'Souza, M.D.
Howard H. Fenn, M.D.
Ellen Frank, Ph.D.
John Geddes, M.D., FRCPsych
Valentim Gentil, M.D., Ph.D.
Samuel Gershon, M.D.
Giovanni de Girolamo, M.D.
Martha Hellander
Chantal Henry, M.D., Ph.D.
Thomas R. Insel, M.D.
Steven Jones, Ph.D.
Athanasio Koukopoulos, M.D.
Brenda E. Lee
Lydia Lewis
Husseini Manji, M.D.
David Miklowitz, Ph.D.
Philip Mitchell, M.D., FRANZCP, FRCPsych
Paolo Lucio Morselli, M.D.
Bruno Müller-Oerlinghausen, Dr.med.
Pamela B. Peele, Ph.D.
Martin Preisig, M.D.
Noreen Reilly-Harrington, Ph.D
Alessandro Rotondo, M.D.
Jan Scott, M.D., FRCPsych
Kenneth I. Shulman, M.D.
Holly A.Swartz, M.D.
Michael E. Thase, M.D.
Per Vestergaard, Dr.Med.Sc.
Adele C. Viguera, M.D.
Robert M. Wettstein, M.D.
Allan H. Young, M.D., Ph.D.
Ari E. Zaretsky, M.D., F.R.C.P.C.
The information presented at this CME program
represents the views and opinions of the individual presenters, and does not
constitute the opinion or endorsement of, or promotion by, the UPMC Center for
Continuing Education in the Health Sciences, UPMC Health System or Affiliates
and University of Pittsburgh School of Medicine. Reasonable efforts have been
taken intending for educational subject matter to be presented in a balanced,
unbiased fashion and in compliance with regulatory requirements. However, each
program attendee must always use his/her own personal and professional judgment
when considering further application of this information, particularly as it may
relate to patient diagnostic or treatment decisions including, without
limitation, FDA-approved uses and any off-label uses.
Acknowledgements
We would like to acknowledge the
following companies for their generous support of this program: Abbott
Laboratories, AstraZeneca Pharmaceuticals,
Bristol-Myers Squibb Company, Forest Laboratories, Inc.,
GlaxoSmithKline, Janssen Pharmaceutica, Eli Lilly
and Company, Novartis, Pfizer, Inc.,
Physicians Postgraduate Press, Inc., Solvay
Pharmaceuticals, and Wyeth-Ayerst Pharmaceuticals.
Top of Page
|
